Stock listing

Xetra:LLY Eli Lilly and Company Aktie

German listing (Xetra) of Eli Lilly and Company · home listing NYSE:LLY

Follow Eli Lilly and Company into a list and get an email when it puts out news.

Share price · XETR:LLY

€1,111.60 EUR -11.80 (-1.1%)

Close on Oct 19, 2026

Day range
€1,106.60 – €1,122.60 EUROct 19, 2026
Volume
1,380 sharesOct 19, 2026
Market cap
€990.8B EURAt the close on Oct 19, 2026 · price × 891.4M shares outstanding
Eli Lilly and Company logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:LLY · Home$1,283.66 USD+43.32 (+3.5%)2,958,921$1,263.50$1,311.75$1,260.17$1,240.34Close on Oct 20, 2026
Xetra:LLY€1,111.60 EUR-11.80 (-1.1%)1,380€1,118.20€1,122.60€1,106.60€1,123.40Close on Oct 19, 2026
BCBA:LLY$37,380 ARS+1,340 (+3.7%)53,012$36,720$38,080$36,720$36,040Close on Oct 20, 2026
B3:LILY34208.58 BRL-3.80 (-1.8%)43,505210.50211.84208.58212.38Close on Oct 19, 2026
TSX:LLY$44.29 CAD-0.59 (-1.3%)55,320$44.35$44.89$44.29$44.88Close on Oct 19, 2026
Cboe Canada:LLY$44.51 CAD-0.23 (-0.5%)6,114$44.42$44.70$44.42$44.74Close on Oct 19, 2026
BMV:LLY$23,710 MXN+696 (+3.0%)98$23,922$23,922$23,600$23,014Close on Oct 20, 2026
Frankfurt:LLY€1,142.00 EUR+27.00 (+2.4%)111€1,109.40€1,156.40€1,109.40€1,115.00Close on Oct 20, 2026
SIX Swiss:LLY1,040.00 CHF-10.00 (-1.0%)—955.001,040.00955.001,050.00Close on Oct 19, 2026
Dusseldorf:LLY€1,150.00 EUR+37.80 (+3.4%)—€1,106.20€1,154.60€1,106.20€1,112.20Close on Oct 20, 2026
Hamburg:LLY€1,153.60 EUR+43.60 (+3.9%)3€1,107.00€1,156.20€1,107.00€1,110.00Close on Oct 20, 2026
Munich:LLY€1,109.40 EUR-2.80 (-0.3%)—€1,109.40€1,109.40€1,109.40€1,112.20Close on Oct 20, 2026
Cboe Canada:ZLLY$13.18 CAD-0.10 (-0.8%)392$13.21$13.22$13.18$13.28Close on Oct 19, 2026
Ticker
Xetra:LLY
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Xetra
Currency
EUR

What changed lately

Calls

Upcoming

  • Eli Lilly and (NYSE:LLY) Q3 2026 Earnings Call

    Thu, Oct 29, 2026 · 10:00 AM ET

    Register

Replays

  • Eli Lilly and (NYSE:LLY) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 10:00 AM ET

    Watch Transcript

  • Eli Lilly and (NYSE:LLY) Q1 2026 Earnings Call

    Thu, Apr 30, 2026 · 10:00 AM ET

    Watch Transcript

  • Eli Lilly and (NYSE:LLY) Q4 2025 Earnings Call

    Wed, Feb 04, 2026 · 10:00 AM ET

    Watch Transcript

Latest news

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Oct 19, 2026

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Oct 18, 2026

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

Oct 15, 2026

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

Oct 15, 2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Oct 9, 2026

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

Oct 5, 2026

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

Oct 2, 2026

Lilly Pulitzer supports The Pink Agenda with 'petals with a purpose' Print capsule for breast cancer awareness month

Oct 1, 2026

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

Oct 1, 2026

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

Oct 1, 2026

All Eli Lilly and Company news

Decks

Eli Lilly and Company on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
191 in the last 12 months · 191 in all · newest Oct 19, 2026 · oldest 2025
Calls
31 calls with a replay · 31 with a transcript · latest Aug 5, 2026
Decks
32 decks · latest Aug 5, 2026

Where Eli Lilly and Company is listed

ListingExchangeCountryCurrency
NYSE:LLY · Home listingNYSEUnited StatesUSD
gettex:LLYgettexGermanyEUR
SET:LLY80SETThailandTHB
GPW:LILYGPWPolandPLN
Xetra:LLY · This pageXetraGermanyEUR
BCBA:LLYBCBAArgentinaARS
B3:LILY34B3BrazilBRL
Tradegate:LLYTradegateGermanyEUR
LS Exchange:858560LS ExchangeGermanyEUR
TSX:LLYTSXCanadaCAD
Cboe Canada:LLYCboe CanadaCanadaCAD
BMV:LLYBMVMexicoMXN
Milan:1LLYMilanItalyEUR
BCBA:LLYDBCBAArgentinaUSD
BOATS:LLYBOATSUnited StatesUSD
Lang & Schwarz:858560Lang & SchwarzGermanyEUR
Frankfurt:LLYFrankfurtGermanyEUR
SIX Swiss:LLYSIX SwissSwitzerlandCHF
Dusseldorf:LLYDusseldorfGermanyEUR
EUROTLX:4LLYEUROTLXItalyEUR
BCS:LLYCLBCSChileCLP
Stuttgart:LLYStuttgartGermanyEUR
Hamburg:LLYHamburgGermanyEUR
BIVA:LLYBIVAMexicoMXN
Munich:LLYMunichGermanyEUR
Cboe Canada:ZLLYCboe CanadaCanadaCAD
BX Swiss:LLYUSDBX SwissSwitzerlandUSD
BCBA:LLYCBCBAArgentinaUSD
Aquis:LLYDAquisUnited KingdomEUR
LSE:0Q1GLSEUnited KingdomCHF
Aquis:LLYZAquisUnited KingdomCHF
VIE:LLYCViennaAustriaEUR
gettex:LLY0gettexGermanyEUR
Aquis:LLYDAquisUnited KingdomEUR
BX Swiss:LLYBX SwissSwitzerlandCHF
BCS:LLYBCSChileUSD
BSESOF:LLYBSESOFBulgariaEUR
Hanover:LLYHanoverGermanyEUR
BCBA:LLYBBCBAArgentinaARS
Turquoise:LLYNTurquoiseUnited KingdomUSD
BVL:LLYUSBVLPeruPEN
Turquoise:LLYZTurquoiseUnited KingdomCHF
Frankfurt:LLY0FrankfurtGermanyEUR
Frankfurt:LLY1FrankfurtGermanyEUR
LS Exchange:A3ETW6LS ExchangeGermanyEUR
Munich:LLY0MunichGermanyEUR
Dusseldorf:LLY0DusseldorfGermanyEUR
Hamburg:LLY0HamburgGermanyEUR
Lang & Schwarz:A3ETW6Lang & SchwarzGermanyEUR
BCBA:LLY.CIBCBAArgentinaARS
BCS:LLYCL1BCSChileUSD
SET:LLY23SETThailandTHB

Log in to ask 6ix AI your own questions about Eli Lilly and Company.